StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report released on Friday. The brokerage issued a hold rating on the stock.

Several other analysts have also recently weighed in on EKSO. Lake Street Capital started coverage on Ekso Bionics in a report on Monday, June 24th. They issued a “buy” rating and a $2.50 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Ekso Bionics in a report on Tuesday, July 30th.

Ekso Bionics Stock Performance

Shares of EKSO opened at $1.05 on Friday. The stock’s 50-day simple moving average is $1.09 and its 200 day simple moving average is $1.17. The stock has a market capitalization of $19.08 million, a price-to-earnings ratio of -1.08 and a beta of 1.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.77 and a current ratio of 2.42. Ekso Bionics has a 52-week low of $0.75 and a 52-week high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, July 29th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. The business had revenue of $4.95 million during the quarter, compared to analysts’ expectations of $5.34 million. During the same period in the previous year, the business earned ($0.31) EPS. Research analysts forecast that Ekso Bionics will post -0.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC grew its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.